Although glycated haemoglobin (HbA1c) has become the key biochemical marker of long-term glycaemic control, analytical method-dependent differences in results can occur when haemoglobin variants are present or HbA1c is reduced by decreased red cell survival. When the measured HbA1c level is discordant with the patient’s blood glucose measurements and clinical status, fructosamine is an alternative biochemical marker that can provide a more accurate estimate of the glycaemic control and enable clinicians to appropriately manage patients.
A 65-year-old, centrally obese man (body mass index, 32.7 kg/m2) with a 23-year history of type 2 diabetes mellitus was referred to a diabetes clinic in January 2008 for stabilisation of his blood sugar levels. His diabetes was complicated by ischaemic heart disease, peripheral vascular disease, hypertension, dyslipidaemia, and stage 3 chronic kidney disease. His glycated haemoglobin (HbA1c) level on referral was 11.0%, measured using an ion-exchange chromatography (IEC) method on a Bio-Rad Variant II analyser (Bio-Rad Laboratories, Sydney, NSW), and the laboratory fasting glucose measurement was 19.3 mmol/L (Box 1). Both these results were consistent with the patient’s home blood glucose measurements (> 10 mmol/L).
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Higgins TN, Blakney GB, Dayton J. Analytical evaluation of the Bio-Rad Variant II automated HbA1c analyzer. Clin Biochem 2001; 34: 361-365.
- 2. Globin Gene Server [website]. http://globin.cse.psu.edu (accessed Dec 2008).
- 3. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assay for glycohemoglobin. Clin Chem 2001; 47: 153-163.
- 4. Schnedl WJ, Lahousen T, Lang T, et al. Determination of glycated hemoglobin in clinically silent hemoglobin variants. Diabetes Metab Res Rev 2004; 20: 460-465.
- 5. Goodall I, Colman PG, Schneider HG, et al. Desirable performance standards for HbA1c analysis – precision, accuracy and standardisation: consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA). Clin Chem Lab Med 2007; 45: 1083-1097.
- 6. Kosecki SM, Rodgers PT, Adams MB. Glycemic monitoring in diabetics with sickle cell plus beta-thalassemia hemoglobinopathy. Ann Pharmacother 2005; 39: 1557-1560.
- 7. Chang J, Hoke C, Ettinger B, Penerian G. Evaluation and interference study of hemoglobin A1c measured by turbidimetric inhibition immunoassay. Am J Clin Pathol 1998; 109: 274-278.
- 8. Macdonald DR, Hanson AM, Holland MR, Singh BM. Clinical impact of variability in HbA1c as assessed by simultaneously measuring fructosamine and use of error grid analysis. Ann Clin Biochem 2008; 45: 421-425.
- 9. Goldstein DE, Little RR, Lorenz RA, et al; American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care 2003; 26 Suppl 1: S106-S108.
- 10. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007; 30: 2399-2400.
- 11. Australian Department of Immigration and Citizenship. Settler arrival data: selected countries of birth by migration stream for the financial year 2007–08. http://www.immi.gov.au/media/statistics/statistical-info/oad/settlers/setdatb.htm (accessed Aug 2009).
None identified.